https://acrabstracts.org/abstract/a-phase-3-randomized-controlled-trial-of-anifrolumab-in-patients-with-moderate-to-severe-systemic-lupus-erythematosus/
A Phase 3 Randomized Controlled Trial of Anifrolumab in Patients with Moderate to Severe Systemic...
Background/Purpose: In a phase 2 study in SLE patients (pts), substantial efficacy was observed with anifrolumab, a human monoclonal antibody that binds the...
randomized controlled trialin patientsphaseanifrolumabmoderate
https://medicalupdateonline.com/2022/11/anifrolumab-shows-long-term-promise-in-patients-with-lupus/
Anifrolumab shows long-term promise in patients with lupus - Medical Update Online
Nov 16, 2022 - Type I interferon (IFN) is a powerful immune activator that is present at high levels in the majority of patients with lupus, an autoimmune disease. In...
long termin patientsmedical updateanifrolumabshows
https://adisinsight.springer.com/drugsafety/803928461?error=cookies_not_supported&code=63b7acd2-9801-4996-bf14-62abba384267
Anifrolumab - AdisInsight
A cohort of 206 patients with systemic lupus erythematosus, including 183 women with a mean age of 44.6 years, received anifrolumab [dose, route, treatment
anifrolumab
https://www.sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/saphnelo-anifrolumab-fnia
Saphnelo (anifrolumab-fnia) | Sentinel Initiative
saphneloanifrolumabsentinelinitiative